Biogen Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Biogen Inc. (BIIB)

Biogen shares dropped 6.4% after Phase 2 CELIA trial data revealed information absent from the Company's filings. NEW YORK, May 15, 2026 /PRNewswire/ -- Biogen Inc. (NASDAQ: BIIB) investors lost approximately 6.4% per share on May 14, 2026, after Phase 2 "CELIA" topline data for...